Enhertu for HER2-Low Breast Cancer
At the recent 2022 American Society of Clinical Oncology Annual Meeting, researchers presented results showing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki), which is a type of medicine doctors call an antibody-drug conjugate, improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
Listen to the podcast to hear Dr. Wojciechowski explain:
what HER2-low breast cancer is
how Enhertu works
how the results of the DESTINY-Breast-04 study will change practice
Editor’s Note: On Aug. 5, 2022, the U.S. Food and Drug Administration (FDA) approved Enhertu to treat unresectable or metastatic HER2-low breast cancer in people who have previously received chemotherapy:
for metastatic disease
after surgery for early-stage disease that came back (recurred) within six months of completing chemotherapy
Unresectable means the cancer can’t be removed with surgery.
Dr. Wojo is a medical oncologist outside of Philadelphia, PA, with Crozer Health. His research has been presented at the San Antonio Breast Cancer Symposium, and he is a speaker on medical ethics and the biology of cancer. Dr. Wojo sees cancer as a scientifically complex disease with psychological, social, and spiritual dimensions.
— Last updated on August 8, 2022, 9:24 PM